CollPlant Biotechnologies Ltd. (CLGN) reported its first quarter 2025 financial results and provided a comprehensive corporate update highlighting progress across its regenerative and aesthetic medicine pipeline.
The Israel-based company develops tissue regeneration and aesthetic products using its proprietary, non-animal recombinant human collagen or rhCollagen. Its platform supports applications in breast implants, dermal fillers, and bioinks for 3D bioprinting.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com